Skip to main content

Table 1 Table summarizing the proportion of estrogen (ER) and progesterone receptor (PR) positive tumor cells, the results from HER2 immunohistochemistry (IHC) and silver in situ hybridization (SISH), the Ki67 proliferation rate as well as histopathological grading of LowHR samples included in this study

From: DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status

Case # ER (%) PR (%) HER2 IHC HER2 SISH Ki67 (%) Grading cT cN
1 8 0 1+ Not done 80 G3 cT2 cN−
2 5 0 3+ Not done 30 G3 cT2 cN+
3 2 0 3+ Positive 15 G2 cT2 cN+
4 5 0 2+ Positive 40 G3 cT2 cN+
5 5 0 3+ Positive 15 G2 cT2 cN−
6 5 0 3+ Positive 40 G3 cT2 cN−
7 5 0 3+ Not done 30 G3 cT2 cN+
8 0 3 1+ Not done 90 G3 cT1 cN−
9 5 0 2+ Negative 70 G3 cT2 cN−
10 0 5 3+ Not done 70 G3 cT2 cN−
11 3 0 0 Not done 80 G3 cT3 cN+
12 5 0 0 Not done 80 G3 cT1 cN+
13  < 1 8 3+ Not done 20 G3 cT4 cN+
14 5 0 0 Not done 50 G3 cT1 cN+
15 8 8 3+ Not done 73 G3 cT2 cN+
16 2 0 2+ Negative 50 G3 cT2 cN−
17 3 2 2+ Negative 85 G3 cT1 cN−
18 3  < 1 3+ Not done 40 G3 cT2 cN−
19 3 0 2+ Negative 30 G3 cT2 cN−
20 0 5 0 Not done 95 G3 cT2 cN−
21 2 0 2+ Positive 90 G3 cT2 cN−
22 0 5 3+ Not done 38 G3 cT2 cN−
23 2 0 3+ Not done 35 G3 cT2 cN+